Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
The Francis Crick Institute · Cancer Research UK · +74 more institutions
Abstract
Circulating tumor DNA (ctDNA) detection can predict clinical risk in early-stage tumors. However, clinical applications are constrained by the sensitivity of clinically validated ctDNA detection approaches. NeXT Personal is a whole-genome-based, tumor-informed platform that has been analytically validated for ultrasensitive ctDNA detection at 1-3 ppm of ctDNA with 99.9% specificity. Through an analysis of 171 patients with early-stage lung cancer from the TRACERx study, we detected ctDNA pre-operatively within 81% of patients with lung adenocarcinoma (LUAD), including 53% of those with pathological TNM (pTNM) stage I disease. ctDNA predicted worse clinical outcome, and patients with LUAD with
Citation impact
- FWCI
- 55.62
- Percentile
- 100%
- References
- 35
Authors
280- JRJames R. BlackCorresponding
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, University College London
- GBGábor Bartha
Personalis (United States)
- CWCharles W. Abbott
Personalis (United States)
- SMSean Michael Boyle
Personalis (United States)
- TKTakahiro Karasaki
The Francis Crick Institute, Cancer Research UK, London Cancer, CRUK Lung Cancer Centre of Excellence, Toranomon Hospital, University College London
Topics & keywords
- Adenocarcinoma
- Stage (stratigraphy)
- Medicine
- Risk stratification
- Oncology
- Internal medicine
- Disease
- Lung
- Good health and well-being
Funding
- BABrigham and Women's Hospital
- MGMassachusetts General Hospital
- AUAarhus Universitet
- AUAarhus Universitetshospital
- IFInstitut for Klinisk Medicin, Aarhus Universitet
- WTWellcome TrustAwards: CC2041, 211179/Z/18/Z
- UHUniversity Hospital Southampton NHS Foundation Trust
- FCFrancis Crick InstituteAward: CC2041
- NGNHS Greater Glasgow and Clyde
- KIKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- CRCancer Research UKAwards: C7893/A26233, C416/A21999, A17786, C416/, ID16584, C11496/A17786, CC2041
- NINational Institute for Health and Care Research
- ICImperial College London
- UCUniversity College LondonAward: UCL/12/0279
- RTRosetrees TrustAward: ID16584
- UOUniversity of Glasgow
- UMUniversiteit Maastricht
- SESemmelweis Egyetem
- UOUniversity of Surrey
- KLKU Leuven
- PMPeter MacCallum Cancer Centre
- UZUniversität zu Köln
- ELEötvös Loránd Tudományegyetem
- UKUniversitätsklinikum Köln
- STSheffield Teaching Hospitals NHS Foundation Trust
- CLCRUK Lung Cancer Centre of ExcellenceAward: C11496/ A30025
- RKRobert Koch Institut
- UOUniversity of Texas MD Anderson Cancer Center
- MRMedical Research CouncilAward: CC2041
- JSJapan Society for the Promotion of Science
- CSCARIM School for Cardiovascular Diseases, Universiteit Maastricht